MetaCap

Capricor Therapeutics Inc. (CAPR)

NASDAQ: CAPRHealth CareBiotechnology: Pharmaceutical PreparationsUSD

7.59+0.06 (+0.80%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CAPR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$441.30M
EPS (TTM)
-$2.65
52-week range
2.96 – 40.37
Day range
7.38 – 8.34
Volume / Avg
10.65M / 4.73M
Beta
—

52-week range

$2.96$40.37

CAPR stock today

Shares of Capricor Therapeutics (CAPR) finished higher on Nov 20 at $7.59, a gain of 0.80% or $0.06 per share, versus the S&P 500's 3.70% decline. Volume was 2.2x the average at 10.65M shares, a sign of unusually heavy trading. At this level, CAPR sits near the bottom of its 52-week range of $2.96 to $40.37: 81.2% below the high, set on Dec 3, 2025 and 156.4% above the low.

CAPR is down 73.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 32.0%. Capricor Therapeutics has posted a net loss over the last twelve months (EPS of -$2.65), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Capricor Therapeutics

Company profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Linda Marbán Ph.D.
Headquarters
San Diego, CA
Employees
231

Financial highlights

Full financials

In fiscal 2025, Capricor Therapeutics generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2024. Capricor Therapeutics reported a net loss of $105.0 million, compared with a loss of $40.5 million a year earlier. Diluted earnings per share came in at -$2.26.

Capricor Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$22.27M$25.18M$2.55M$244.90K
Growth-100.00%-11.55%+886.81%+941.85%-21.06%
Net income$-105.04M$-40.47M$-22.29M$-29.02M$-20.02M
EPS (diluted)$-2.26$-1.15$-0.83$-1.18$-0.87

Analyst forecast

Forecast

Consensus (10 analysts)

buy

Avg. price target

$27.25+259.03%

  • Strong buy 1
  • Buy 4
  • Hold 5
  • Sell 0
  • Strong sell 0

Target range

Low $10.50High $54.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.54 vs $-0.61
Surprise
+11.48%

CAPR news

All CAPR news

Capricor Therapeutics peers

Health Care sector
CAPR peer companies
CompanyPrice% ChgMarket capCompare
AQSTAquestive Therapeutics Inc.3.46-6.61%$434.88Mvs CAPR
LYELLyell Immunopharma Inc.13.80+1.62%$441.82Mvs CAPR
INDPIndaptus Therapeutics Inc.2.82-9.90%$433.16Mvs CAPR
CTMXCytomX Therapeutics Inc.2.03-0.98%$442.55Mvs CAPR
EOLSEvolus Inc.6.52-6.86%$431.55Mvs CAPR
AMRNAmarin Corporation plc10.57-6.13%$444.39Mvs CAPR
DMACDiaMedica Therapeutics Inc.8.25+2.87%$445.15Mvs CAPR
KMDAKamada Ltd.7.74-1.15%$446.85Mvs CAPR

Indexes, lists and sector

Capricor Therapeutics stock FAQ

What is Capricor Therapeutics's stock price today?

CAPR last traded at $7.59 as of Nov 20, 4:00 PM EST, up 0.80% on the day. Prices are delayed at least 15 minutes.

Does Capricor Therapeutics pay a dividend?

No. Capricor Therapeutics does not currently pay a regular cash dividend.

Who is Capricor Therapeutics's CEO?

Dr. Linda Marbán Ph.D. is the chief executive officer of Capricor Therapeutics Inc., which has about 231 employees.

Has CAPR ever split its stock?

Yes. The most recent CAPR stock split was a 1-for-10 split on Jun 5, 2019, one of 2 splits on record.

What is the CAPR 52-week high?

The 52-week high for CAPR is $40.37 and the 52-week low is $2.96. The stock is currently 81.2% below its high.

Compare CAPR